Neurovascular Devices Market by Product (Embolization Devices, Revascularization Devices, Embolic Protection Devices, and Accessory Devices), Disease Pathology (Aneurysm, Arteriovenous Malformation (AVM), Ischemic Stroke, Stenosis, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
- ALL4058999
- 250 Pages
- August 2020
- Healthcare
Neurovascular devices are defined as instruments and machines employed in treatment of various neurovascular disorders. Furthermore, neurovascular disorders include medical conditions that affect blood vessels, which supply the brain and spinal cord with oxygenated blood. Thus, neurovascular devices such as embolization devices, revascularization devices, thrombectomy devices, and embolic protection devices are used in treatment of neurovascular disorders.
These devices are used in disorders such as aneurysm. For instance, embolization devices are used in occlusion of blood vessels to reduce blood flow, which, in turn, aids in reduction of blood flow. Similarly, other neurovascular devices such as thrombectomy devices are used in disorders such as ischemic stroke. For instance, these thrombectomy devices aid in recovering the brain from ischemic condition if it has not attained the stage of complete infarction. Thus, these devices restore perfusion through blocked artery.
The major factor that contributes toward growth of the neurovascular devices market include surge in geriatric population. Furthermore, other factors such as rise in prevalence of neurovascular diseases and surge in adoption of neurovascular devices across the globe also contribute to growth of the market. In addition, factors such as surge in technological advancements related to neurovascular devices also boost growth of the neurovascular devices market.
However, high cost of neurovascular devices and dearth of qualified neurosurgeons required to handle these devices restrict growth of the market. Conversely, high growth rate exhibited by developing nations provides lucrative opportunities for players operating in the neurovascular devices market
The global neurovascular devices market is segmented on the basis of product, disease pathology, and region to provide a detailed assessment of the market. By product, the market is divided into embolization devices, revascularization device, thrombectomy devices, embolic protection devices, and accessory devices.
Moreover, these product categories are further divided into sub segments for a profound understanding. For instance, the embolization devices segment is divided into clippings, embolic coils, coil assist stents, and coil assist balloons. In addition, the embolic coils segment is further divided into bare detachable coils and coated detachable coils.
The revascularization device segment is further divided into carotid artery stents and flow diversion stents. In addition, the thrombectomy devices segment is divided into clot retrieval devices, suction & aspiration devices, and snares. The embolic protection devices segment is divided in distal filter devices and balloon occlusion devices. Similarly, the accessory devices segment is divided into microcatheters, and micro guidewires. By disease pathology, the market is classified into aneurysm, arteriovenous malformation (AVM), stenosis, ischemic stroke and others. By region, the neurovascular devices market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The major players in the neurovascular devices market are Medtronic Plc, Stryker Corporation, Penumbra, Inc., Johnson & Johnson, Terumo Corporation, Merit Medical Systems, Inc.., Integer Holdings Corporation, Acandis GmbH., W. L. Gore & Associates, Inc., and Microport Scientific Corporation.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global neurovascular devices market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Product
o Embolization Devices
Clippings
Embolic Coils
• Bare Detachable Coils
• Coated Detachable Coils
Coil Assist Stent
Coil Assist Balloon
o Revascularization Devices
Carotid Artery Stents
Flow Diversion Stents
o Thrombectomy Devices
Clot Retrieval Devices
Suction & Aspiration Devices
Snares
o Embolic Protection Devices
Distal Filter Devices
Balloon Occlusion Devices
o Accessory Devices
Microcatheters
Micro-guidewires
• By Disease Pathology
o Aneurysm
o Arteriovenous Malformation and Fistulas (AVM)
o Ischemic Stroke
o Stenosis
o Others
• By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
• List of key players profiled in the report:
• Medtronic Plc,
• Stryker Corporation
• Penumbra, Inc.
• Johnson & Johnson
• Terumo Corporation
• Merit Medical Systems, Inc.
• Integer Holdings Corporation
• Acandis GmbH
• W. L. Gore & Associates, Inc.
• Microport Scientific Corporation
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Asahi Intecc co., ltd.
• Kaneka Medix Corp.
• Embolx, Inc.
• Wallaby Medical
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top Wining Strategies
3.2.2.Top investment pockets
3.3.Market share analysis, 2019
3.4.Key forces shaping neurovascular devices industry/market
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in geriatric population across the globe
3.5.1.2.Rise in prevalence of neurovascular diseases
3.5.1.3.Increase in prevalence of underlying disease conditions serve as risk neurovascular diseases.
3.5.1.4.Technological advancements related to neurovascular devices
3.5.2.Restraints
3.5.2.1.High cost of neurovascular devices
3.5.2.2.Dearth of neurosurgeons across the globe
3.5.3.Opportunity
3.5.3.1.Opportunities in emerging markets
3.5.4.Impact Analyses
CHAPTER 4:NEUROVASCULAR DEVICES MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Embolization Devices
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Clippings
4.2.2.1.1.Market size and forecast
4.2.2.2.Embolic Coils
4.2.2.2.1.Market size and forecast
4.2.2.2.2.Bare Detachable Coils
4.2.2.2.2.1.Market size and forecast
4.2.2.2.3.Coated Detachable Coil
4.2.2.2.3.1.Market size and forecast
4.2.2.3.Coil assist stent
4.2.2.3.1.Market size and forecast
4.2.2.4.Coil assist balloon
4.2.2.4.1.Market size and forecast
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Revascularization Devices
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Carotid artery stents
4.3.2.1.1.Market size and forecast
4.3.2.2.Flow diversion stents
4.3.2.2.1.Market size and forecast
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Thrombectomy Devices
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Clot Retrieval Devices
4.4.2.1.1.Market size and forecast
4.4.2.2.Suction and Aspiration Devices
4.4.2.2.1.Market size and forecast
4.4.2.3.Snares
4.4.2.3.1.Market size and forecast
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
4.5.Embolic Protection Devices
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by type
4.5.2.1.Distal filter devices
4.5.2.1.1.Market size and forecast
4.5.2.2.Balloon Occlusion Devices
4.5.2.2.1.Market size and forecast
4.5.3.Market size and forecast, by region
4.5.4.Market analysis, by country
4.6.Accessory Devices
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by type
4.6.2.1.Microcatheters
4.6.2.1.1.Market size and forecast
4.6.2.2.Microguidewires
4.6.2.2.1.Market size and forecast
4.6.3.Market size and forecast, by region
4.6.4.Market analysis, by country
CHAPTER 5:NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY
5.1.Overview
5.1.1.Market size and forecast
5.2.Aneurysm
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Arteriovenous Malformation (AVM)
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Ischemic stroke
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Stenosis
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:NEUROVASCULAR DEVICES MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends and opportunities
6.2.2.Market analysis, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. market size and forecast, by product
6.2.2.1.2.U.S. market size and forecast, by disease pathology
6.2.2.2.Canada
6.2.2.2.1.Canada market size and forecast, by product
6.2.2.2.2.Canada market size and forecast, by disease pathology
6.2.2.3.Mexico
6.2.2.3.1.Mexico market size and forecast, by product
6.2.2.3.2.Mexico market size and forecast, by disease pathology
6.2.3.North America market size and forecast, by product
6.2.4.North America market size and forecast, by disease pathology
6.3.Europe
6.3.1.Key market trends and opportunities
6.3.2.Market analysis, by country
6.3.2.1.Germany
6.3.2.1.1.Germany market size and forecast, by product
6.3.2.1.2.Germany market size and forecast, by disease pathology
6.3.2.2.France
6.3.2.2.1.France market size and forecast, by product
6.3.2.2.2.France market size and forecast, by disease pathology
6.3.2.3.UK
6.3.2.3.1.UK market size and forecast, by product
6.3.2.3.2.UK market size and forecast, by disease pathology
6.3.2.4.Italy
6.3.2.4.1.Italy market size and forecast, by product
6.3.2.4.2.Italy market size and forecast, by disease pathology
6.3.2.5.Spain
6.3.2.5.1.Spain market size and forecast, by product
6.3.2.5.2.Spain market size and forecast, by disease pathology
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe market size and forecast, by product
6.3.2.6.2.Rest of Europe market size and forecast, by disease pathology
6.3.3.Europe market size and forecast, by product
6.3.4.Europe market size and forecast, by disease pathology
6.4.Asia-Pacific
6.4.1.Key market trends and opportunities
6.4.2.Market analysis, by country
6.4.2.1.Japan
6.4.2.1.1.Japan market size and forecast, by product
6.4.2.1.2.Japan market size and forecast, by disease pathology
6.4.2.2.China
6.4.2.2.1.China market size and forecast, by product
6.4.2.2.2.China market size and forecast, by disease pathology
6.4.2.3.Australia
6.4.2.3.1.Australia market size and forecast, by product
6.4.2.3.2.Australia market size and forecast, by disease pathology
6.4.2.4.India
6.4.2.4.1.India market size and forecast, by product
6.4.2.4.2.India market size and forecast, by disease pathology
6.4.2.5.South Korea
6.4.2.5.1.South Korea market size and forecast, by product
6.4.2.5.2.South Korea market size and forecast, by disease pathology
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific market size and forecast, by product
6.4.2.6.2.Rest of Asia-Pacific market size and forecast, by disease pathology
6.4.3.Asia-Pacific market size and forecast, by product
6.4.4.Asia-Pacific market size and forecast, by disease pathology
6.5.LAMEA
6.5.1.Key market trends and opportunities
6.5.2.Market analysis, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil market size and forecast, by product
6.5.2.1.2.Brazil market size and forecast, by disease pathology
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia market size and forecast, by product
6.5.2.2.2.Saudi Arabia market size and forecast, by disease pathology
6.5.2.3.South Africa
6.5.2.3.1.South Africa market size and forecast, by product
6.5.2.3.2.South Africa market size and forecast, by disease pathology
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA market size and forecast, by product
6.5.2.4.2.Rest of LAMEA market size and forecast, by disease pathology
6.5.3.LAMEA market size and forecast, by product
6.5.4.LAMEA market size and forecast, by disease pathology
CHAPTER 7:COMPANY PROFILES
7.1.ACANDIS GmbH
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Product portfolio
7.1.4.Key strategic moves and developments
7.2.B. BRAUN MELSUNGEN AG
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.3.INTEGER HOLDINGS CORPORATION
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.JOHNSON & JOHNSON (CERENOVUS)
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.MICROPORT SCIENTIFIC CORPORATION
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.MEDTRONIC PLC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.PENUMBRA, INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.PHENOX GmbH
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Key strategic moves and developments
7.9.STRYKER CORPORATION
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.TERUMO CORPORATION (MICROVENTION, INC.)
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments
TABLE 01.NEUROVASCULAR DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 02.EMBOLIZATION DEVICES, BY TYPE 2019–2027($MILLION)
TABLE 03.EMBOLIC COIL MARKET, BY TYPE 2019–2027($MILLION)
TABLE 04.NEUROVASCULAR DEVICES MARKET FOR EMBOLIZATION DEVICES, BY REGION 2019–2027($MILLION)
TABLE 05.REVASCULARIZATION DEVICES MARKET, BY TYPE 2019–2027($MILLION)
TABLE 06.NEUROVASCULAR DEVICES MARKET FOR REVASCULARIZATION DEVICES, BY REGION 2019–2027($MILLION)
TABLE 07.THROMBECTOMY DEVICES MARKET, BY TYPE 2019–2027($MILLION)
TABLE 08.NEUROVASCULAR DEVICES FOR THROMEBCTOMY DEVICES, BY REGION 2019–2027($MILLION)
TABLE 09.EMBOLIC PROTECTION DEVICES MARKET, BY TYPE 2019–2027($MILLION)
TABLE 10.NEUROVASCULAR DEVICES FOR EMBOLIC PROTECTION DEVICES, BY REGION 2019–2027($MILLION)
TABLE 11.EMBOLIC PROTECTION DEVICES MARKET, BY TYPE 2019–2027($MILLION)
TABLE 12.NEUROVASCULAR DEVICES FOR ACCESSORY DEVICES, BY REGION 2019–2027($MILLION)
TABLE 13.NEUROVASCULAR DEVICES MARKET, BY DISEASE PATHOLOGY, 2019–2027 ($MILLION)
TABLE 14.NEUROVASCULAR DEVICES MARKET FOR ANEURYSM, BY REGION 2019–2027($MILLION)
TABLE 15.NEUROVASCULAR DEVICES MARKET FOR ARTERIOVENOUS MALFORMATION, BY REGION 2019–2027 ($MILLION)
TABLE 16.NEUROVASCULAR DEVICES MARKET FOR ISCHEMIC STROKE, BY REGION 2019–2027 ($MILLION)
TABLE 17.EUROVASCULAR DEVICES MARKET FOR STENOSIS, BY REGION 2019–2027 ($MILLION)
TABLE 18.NEUROVASCULAR DEVICES MARKET FOR OTHERS, BY REGION 2019–2027 ($MILLION)
TABLE 19.NEUROVASCULAR DEVICES MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 20.NORTH AMERICA NEUROVASCULAR DEVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 21.U.S. NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 22.U.S. NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 23.CANADA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 24.CANADA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 25.MEXICO NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 26.MEXICO NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 27.NORTH AMERICA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 28.NORTH AMERICA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027($MILLION)
TABLE 29.EUROPE NEUROVASCULAR DEVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 30.GERMANY NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 31.GERMANY NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 32.FRANCE NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 33.FRANCE NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 34.UK NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 35.UK NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 36.ITALY NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 37.ITALY NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 38.SPAIN NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 39.SPAIN NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 40.REST OF EUROPE NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 41.REST OF EUROPE NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 42.EUROPE NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 43.EUROPE NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027($MILLION)
TABLE 44.ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 45.JAPAN NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 46.JAPAN NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 47.CHINA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 48.CHINA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 49.AUSTRALIA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 50.AUSTRALIA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 51.INDIA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 52.INDIA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 53.SOUTH KOREA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 54.SOUTH KOREA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 55.REST OF ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 56.REST OF ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 58.ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027($MILLION)
TABLE 59.LAMEA NEUROVASCULAR DEVICES MARKET REVENUE, BY COUNTRY, 2020–2027 ($MILLION)
TABLE 60.BRAZIL NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 61.BRAZIL NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 62.SAUDI ARABIA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 63.SAUDI ARABIA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 64.SOUTH AFRICA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 65.SOUTH AFRICA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 66.REST OF LAMEA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027 ($MILLION)
TABLE 67.REST OF LAMEA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027 ($MILLION)
TABLE 68.LAMEA NEUROVASCULAR DEVICES MARKET REVENUE, BY PRODUCT, 2020–2027($MILLION)
TABLE 69.LAMEA NEUROVASCULAR DEVICES MARKET REVENUE, BY DISEASE PATHOLOGY, 2020–2027($MILLION)
TABLE 70.ACANDIS: COMPANY SNAPSHOT
TABLE 71.ACANDIS: PRODUCT PORTFOLIO
TABLE 72.B. BRAUN: COMPANY SNAPSHOT
TABLE 73.B. BRAUN: OPERATING SEGMENTS
TABLE 74.B. BRAUN: PRODUCT PORTFOLIO
TABLE 75.INTEGER: COMPANY SNAPSHOT
TABLE 76.INTEGER: OPERATING SEGMENTS
TABLE 77.INTEGER: PRODUCT PORTFOLIO
TABLE 78.J&J: COMPANY SNAPSHOT
TABLE 79.J&J: OPERATING SEGMENTS
TABLE 80.J&J: PRODUCT PORTFOLIO
TABLE 81.MICROPORT: COMPANY SNAPSHOT
TABLE 82.MICROPORT: OPERATING SEGMENTS
TABLE 83.MICROPORT: PRODUCT PORTFOLIO
TABLE 84.MEDTRONIC: COMPANY SNAPSHOT
TABLE 85.MEDTRONIC: OPERATING SEGMENTS
TABLE 86.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 87.PENUMBRA: COMPANY SNAPSHOT
TABLE 88.PENUMBRA: OPERATING SEGMENTS
TABLE 89.PENUMBRA: PRODUCT PORTFOLIO
TABLE 90.PHENOX: COMPANY SNAPSHOT
TABLE 91.PHENOX: OPERATING SEGMENTS
TABLE 92.PHENOX: PRODUCT PORTFOLIO
TABLE 93.STRYKER: COMPANY SNAPSHOT
TABLE 94.STRYKER: OPERATING SEGMENTS
TABLE 95.STRYKER: PRODUCT PORTFOLIO
TABLE 96.TERUMO: COMPANY SNAPSHOT
TABLE 97.TERUMO: OERATING SEGMENT
TABLE 98.TERUMO: PRODUCT PORTFOLIO
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
